Immusmol
Immusmol was founded in 2012 in Bordeaux, France, developing anti-hapten antibodies targeting kynurenines for diagnostic and therapeutic applications. Over the past decade, Immusmol has speciliased in the development of antibodies against low molecular weight compounds (<900 Daltons), eventually building a portfolio of unique primary antibodies and ELISA kits for research use.
Discover Immusmol antibodies, ELISA kits and staining kits for neurotransmitter, amino acid and tryptophan metabolite detection. Trusted tools for neuroscience and metabolite research.
About Immusmol
Immusmol develops specialised antibodies, ELISA kits and staining solutions for small molecule detection in neuroscience, immunology and metabolite research.
Their product portfolio focuses on neurotransmitters, amino acids, catecholamines, tryptophan metabolites and arginine metabolites, helping researchers analyse biologically important small molecules using reliable immunodetection workflows.
Immusmol products are widely used in:
- Neuroscience research
- Neurodegeneration studies
- Immunometabolism
- Cell signalling research
- Biomarker discovery
- Metabolite analysis
Immusmol Expertise in Small Molecule Detection
Immusmol specialises in anti-hapten antibody development for the detection of small molecules that are traditionally difficult to analyse using standard immunoassay technologies.
Their expertise combines chemistry and immunology to produce highly specific antibodies and immunoassays suitable for research and diagnostic applications.
Key Benefits of Immusmol Products
- Compatible with standard ELISA and immunodetection workflows
- Suitable for multiple species and sample types
- Supports multiplex immunodetection applications
- Available in monoclonal and polyclonal formats
- Designed for sensitive neurotransmitter and metabolite detection
